Compare Infinity Pharmaceuticals (NASDAQ: INFI) and Sol Gel Technologies (SLGL)

Sol Gel Technologies (NASDAQ: INFI) and Infinity Pharmaceuticals (NASDAQ: INFI) are both small pharmaceutical companies, but what is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, recommendations from analysts, profit, profitability and institutional ownership.

Profit and appreciation

This table compares the earnings, earnings per share and valuation of Sol Gel Technologies and Infinity Pharmaceuticals.

Gross income Price / sales ratio Net income Profit per share Price / profit ratio
Sol Gel Technologies $ 170,000.00 695.59 – $ 31.56 million ($ 5.02) -1.25
Infinity Pharmaceuticals $ 6.00 million 18.76 – $ 41.83 million ($ 0.83) -2.39

Sol Gel Technologies has higher revenues, but lower revenues than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-earnings ratio than Sol Gel Technologies, indicating that it is currently the more affordable of the two stocks.


This table compares Sol Gel Technologies and the net margins of Infinity Pharmaceuticals, the return on equity and the return on assets.

Net margins Return on equity Return on assets
Sol Gel Technologies N / A N / A N / A
Infinity Pharmaceuticals N / A -64.18% -54.82%

Analyst Ratings

This is a summary of the current recommendations for Sol Gel Technologies and Infinity Pharmaceuticals, as reported by MarketBeat.

Sales reviews Keep ratings Buy ratings Strong sales figures Review score
Sol Gel Technologies 0 0 4 0 3.00
Infinity Pharmaceuticals 0 0 2 0 3.00

Sol Gel Technologies currently has a target price of $ 19.00, indicating a potential increase of 204.00%. Infinity Pharmaceuticals has a consensus target price of $ 4.00, suggesting a potential benefit of 102.02%. Given the higher possible upward impact of Sol Gel Technologies, research analysts clearly believe that Sol Gel Technologies is more beneficial than Infinity Pharmaceuticals.

Institutional and Insider ownership

23.6% of the Sol Gel Technologies shares are held by institutional investors. In comparison, 45.2% of Infinity Pharmaceuticals shares are held by institutional investors. 11.5% of Infinity Pharmaceuticals shares are owned by insiders of companies. Strong institutional ownership is an indication that large money managers, donations and hedge funds think that a share will outperform the market in the long term.


Sol Gel Technologies beats Infinity Pharmaceuticals on 7 out of 11 compared to the two stocks.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a pharmaceutical company in the clinical phase, focuses on the development and commercialization of topical dermatological drugs based on its own system for providing microencapsulation in Israel. The main product candidates of the company are TWIN and SIRS-T, which has completed phase II clinical trials for the treatment of acne vulgaris; and VERED who completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological medicines. Sol-Gel Technologies Ltd. has a partnership with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. The product candidate is IPI-549, an orally administered clinical phase immuno-oncological product candidate that inhibits the enzyme phosphoinositide-3-kinase gamma (PI3K-gamma), which is part of phase 1 / 1b clinical trial. The company has strategic alliances with Intellikine, Inc. to discover, develop and commercialize pharmaceutical products that focus on the delta and / or gamma isoforms of PI3K; Verastem, Inc. for research into, development, commercialization and production of duvelisib and products containing duvelisib, as well as duvelisib program, including DUO research that is part of Phase III clinical trial and recurrence for patients with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. for the development and commercialization of rights to its hedgehog-inhibiting program, IPI-926, candidate for a clinical stage of a product; and AbbVie Inc. to develop and market products with duvelisib in oncological indications, as well as a cooperation agreement with Arcus Biosciences, Inc. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive news and ratings for Sol Gel Technologies Daily – Please provide your email address below for a concise, daily summary of the latest news and ratings from analysts for Sol Gel Technologies and related companies with the FREE daily email newsletter from

Source link

Leave a Reply